Palivizumab
Indications
Palivizumab is used for:
Indicated for the prevention of serious, lower respiratory tract disease, caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease, Passive immunisation of infants against, lower respiratory tract infections
Adult Dose
Not indicated
Child Dose
Intramuscular
Child:
RSV Prophylaxis
Indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease
15 mg/kg IM q1Month during RSV season with first dose administered prior to the season
Renal Dose
Administration
Contra Indications
Hypersensitivity to palivizumab or other humanised monoclonal antibodies.
Precautions
Patient w/ thrombocytopenia or other coagulation disorder, moderate to severe acute infection or febrile illness. Not intended for use in adult. Pregnancy and lactation.
Pregnancy-Lactation
Pregnancy
Not indicated for use in females of reproductive potential
Lactation
Not indicated for use in females of reproductive potential
Lactation: no studies done
Interactions
Side Effects
Side effects of Palivizumab :
>10%
Fever (27%)
Rash (26%)
1-10%
Antibody formation (1-2%)
<1%
Pain
Hernia
SGOT increased
Cough
Bronchiolitis
Pneumonia
Dyspnea
Sinusitis
Apnea
Thrombocytopenia
Failure to thrive
Diarrhea
Vomiting
Conjunctivitis
Eczema
Anemia
Angioedema
Flu syndrome
Mode of Action
Palivizumab is a recombinant humanised monoclonal antibody which targets the surface glycoprotein, responsible for recognition and entry into the cell on the resp syncytial virus (RSV).